Atrial fibrillation
Conditions
Interventions
Experimental Group:None
Control group:None
Sponsors
Beijing Anzhen Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Subjects who participated in the "Clinical Trial on the Short-term Efficacy and Safety of Cardiac Electrophysiological Interventional Device Control System Combined with Disposable Electrophysiological Interventional Device Support for Assisted Catheter Ablation of Atrial Fibrillation (Protocol Number: MAXC-CTO-HN-2021-0047)" and completed 3 months of follow-up after surgery were included. This study did not set additional inclusion and exclusion criteria.
Exclusion criteria
Exclusion criteria: Subjects who have not participated in the "Clinical Trial on the Short-term Effectiveness and Safety of Cardiac Electrophysiology Interventional Device Control System Combined with Disposable Electrophysiology Interventional Device Support for Assisted Atrial Fibrillation Catheter Ablation (Protocol Number: MAXCCTO-HN-2021-0047)" (this clinical trial is used to study the medical device registration application of the device, so it is referred to as the "Registration Clinical Trial") and completed the 3-month follow-up after surgery, including subjects in the experimental group and the control group
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative recurrence rate;Atrial fibrillation quality of life; | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgical complication rate;Adverse event rate;Incidence of serious adverse events; | — |
Countries
CHINA
Contacts
Public ContactCAIHUA SANG
Beijing Anzhen Hospital Affiliated to Capital Medical University
Outcome results
None listed